Skip to content

Advertisement

  • Poster presentation
  • Open Access

Human cancer cells respond to cytosolic nucleic acids via enhanced production of interferon-β and apoptosis

  • 1,
  • 1,
  • 1,
  • 1,
  • 2 and
  • 3
Journal for ImmunoTherapy of Cancer20153(Suppl 2):P250

https://doi.org/10.1186/2051-1426-3-S2-P250

Published: 4 November 2015

Keywords

  • Cancer Cell
  • Gastric Cancer
  • Pancreatic Cancer
  • Cervical Cancer
  • Pancreatic Cancer Cell

The innate immune system utilizes pattern-recognition receptors (PRRs) to detect the invasion of pathogens and initiate host antimicrobial responses. Recently, it was reported that human cancer cells also expressed PRRs, and responded to cytosolic nucleic acids via the production of type I interferon and apoptosis in susceptible cells. However, the definite nucleic acids senses in different cancer cells remains unclear. In this study, we investigated the effects of nucleic acids in eight types of cancer cells, including pancreatic cancer, glioma, breast cancer, lung cancer, hepatoma, gastric cancer, colorectal cancer, and cervical cancer. We found that IFN-β secretion was increased after poly(I:C) and poly(dA:dT) stimulation. In order to understand the mechanism, we established the role of TLR3 and RIG-I/MDA-5 signaling in pancreatic cancer cell line PANC-1. poly(I:C) and poly(dA:dT) upregulated the expression of PKR, TLR3, RIG-I, MDA5 and LGP2. Knockdown experiments confirmed PKR, TLR3, TRIF, RIG-I, LGP2, and IPS-1 involved in response to cytosolic poly(I:C) and poly(dA:dT). In addition, poly(I:C) and poly(dA:dT) induced apoptosis via caspase-8 and caspase-9 in pancreatic cancer cells. In summary, cytosolic poly(I:C) and poly(dA:dT) induce IFN-β secretion via TLR3-TRIF and RIG-I/LGP2-IPS-1 signaling pathway and apoptosis in a caspase-dependent manner at cancer cells. This study may provide a novel way for drug and vaccine design on cancer immunotherapy.

Authors’ Affiliations

(1)
Institute of Translational Medicine, the First Hospital, Jilin University, Changchun, China
(2)
MedImmune, Gaithersburg, China
(3)
Institute of Translational Medicine, the First Hospital, Jilin University, Changchun, China

Copyright

© Zhu et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement